New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms

Código QR

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms

Guardado en:

Detalles Bibliográficos
Autores principales:	Hans C. Hasselbalch, Richard T. Silver
Formato:	article
Lenguaje:	EN
Publicado:	Wolters Kluwer 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/161b2c12c78d406dba9f9777c72a3bf4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

THE OUTCOME OF FATHERHOOD IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS, A SINGLE INSTITUTION EXPERIENCE
por: Elrazi Ali, et al.
Publicado: (2021)

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]
por: Anagnostou T, et al.
Publicado: (2018)

INFLAMMATION AND CANCER
por: Jean-François Rossi
Publicado: (2021)

Cytogenetic studies for cMYC, BCL2 and BCL6 genes in neoplasm: comparison of karyotype, FISH in paraffin-embedded tissue and FISH in methanol-acetic acid-fixed cells suspensions
por: Caroline Henriques Garcia, et al.
Publicado: (2021)

THE APPROACH AND DIAGNOSIS OF COOMBS NEGATIVE HEMOLYTIC ANEMIAS
por: Achille Iolascon
Publicado: (2021)

HOW I TREAT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS?
por: María-Victoria Mateos
Publicado: (2021)

Treating the elderly patient with chronic lymphocytic leukemia: current and emerging options
por: Mozaheb Z
Publicado: (2014)

Leptomeningeal myelomatosis in previously treated high-risk kappa light chain multiple myeloma: case report and literature review
por: Ohanian M, et al.
Publicado: (2011)

ACQUIRED FACTOR XIII DEFICIENCY WITH RUNX1 MUTATION, A REPORT OF TWO CASES TREATED WITH FACTOR XIII CONCENTRATE
por: Alfadil Haroon, et al.
Publicado: (2021)

REVIEW OF NEW INDICATIONS – JOURNAL OF CLINICAL APHERESIS PERSPECTIVE
por: Huy Pham
Publicado: (2021)

Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose
por: Waclaw J, et al.
Publicado: (2015)

Trends in the treatment of cutaneous T-cell lymphoma &ndash; critical evaluation and perspectives on vorinostat
por: Zhang CL, et al.
Publicado: (2012)

MicroRNA dysregulation in B-cell non-Hodgkin lymphoma
por: Lim EL, et al.
Publicado: (2013)

Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
por: Bodiford A, et al.
Publicado: (2015)

The expanding role of bendamustine in chronic lymphocytic leukemia
por: Nair KS, et al.
Publicado: (2015)

Bortezomib in autoimmune hemolytic anemia and beyond
por: Raffaella Pasquale, et al.
Publicado: (2021)

Life-Threatening Retroperitoneal Hematoma in a Patient with COVID-19
por: Monarch Shah, et al.
Publicado: (2021)

A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment
por: Jennifer Gill, et al.
Publicado: (2020)

All bleeding matters … but the details may not
por: Sarah H. O’Brien
Publicado: (2020)

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
por: Eko A. Pangarsa, et al.
Publicado: (2021)

PP Transcon 2020 Abstracts Compilation
Publicado: (2021)

Positive/external control of rapid diagnostic tests: A step forward in malaria screening
por: Rasika D Setia, et al.
Publicado: (2021)

A rare case of mistaken identity - Historical blood group saved the situation
por: Anand Deshpande, et al.
Publicado: (2021)

Oration - Dr Sanmukh Joshi
Publicado: (2021)

OP Transcon 2020 Abstracts Compilation
Publicado: (2021)

TRANSCON 2020 45th Annual Conference ISBTI 27th & 28th Feb 2021
Publicado: (2021)

Clinical relevance of hepatitis B core total antibody in the detection of occult hepatitis B infection in patients with liver disease and blood donors
por: Vijeta Bajpai, et al.
Publicado: (2021)

Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib
por: Shoumariyeh K, et al.
Publicado: (2014)

MYC as therapeutic target in leukemia and lymphoma
por: Cortiguera MG, et al.
Publicado: (2015)

Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
por: Gupta VA, et al.
Publicado: (2013)

Optimal management of endemic Burkitt lymphoma: a holistic approach mindful of limited resources
por: Moormann AM, et al.
Publicado: (2014)

Peripheral T cell lymphoma: clinical utility of romidepsin
por: Sawey K, et al.
Publicado: (2012)

The evaluation and optimal use of rituximab in lymphoid malignancies
por: Smolewski P, et al.
Publicado: (2012)

Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program
por: Samuel sarmiento Doncel, et al.
Publicado: (2021)

Ultrastructural alterations of megakaryocytes in thrombocytopenia: A review of 43 cases
por: Brian Eyden, et al.
Publicado: (2021)

Regulation of megakaryopoiesis by bone marrow macrophage polarization
por: Ming Hou
Publicado: (2021)

The correlation between Flt3-ITD mutation in dendritic cells with TIM-3 expression in acute myeloid leukemia
por: Hooriyeh Shapoorian, et al.
Publicado: (2021)

Immune targeted therapy for diffuse large B cell lymphoma
por: Yaxin Zheng, et al.
Publicado: (2021)

Lymphoid-biased hematopoietic stem cells and myeloid-biased hematopoietic progenitor cells have radioprotection activity
por: Shanshan Zhang, et al.
Publicado: (2021)

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
por: Meletios A. Dimopoulos, et al.
Publicado: (2021)